Nerviano Medical Sciences
Alessio Somaschini is a researcher at Nerviano Medical Sciences, part of the NMS Group, since May 2011, focusing on molecular profiling of clinical samples and cancer biomarker discovery using advanced NGS assays and molecular biology techniques. Somaschini contributes to the R&D pipeline with a strong emphasis on genomics and cancer target identification. With expertise in NGS, Sanger sequencing, molecular biology methods, and high-throughput screening technologies, Somaschini also held roles as a trainee researcher and research fellow at various institutions, including the University of Milan and Università degli Studi di Milano-Bicocca, where foundational experience in molecular characterization and bioinformatics was gained. Somaschini holds a Master of Science in Industrial Biotechnology and a Bachelor of Science in Molecular Biotechnology from Università degli Studi di Milano-Bicocca.
This person is not in any offices
Nerviano Medical Sciences
Nerviano Medical Sciences is part of NMS Group and it is focused on the discovery and early development of oncology drugs. Our business model is to partner our drugs at late preclinical or early clinical stage for full development and commercialization. Our mission is to pursue innovative therapeutic approaches in Oncology, discovering and developing molecules with novel mechanisms of action, for the advancement of personalized care of cancer patients. An experienced and lean management team leads a highly skilled staff of professionals with international experience and a broad range of expertise in R&D, combining the flexibility of a biotech with the quality standards of a big pharma.